Petros Pharmaceuticals, Inc.
PTPI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 63.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $2 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $8 |
| Operating Expenses | $1 | $2 | $1 | $10 |
| Operating Income | -$1 | -$2 | -$1 | -$9 |
| % Margin | – | – | – | -1,258.7% |
| Other Income/Exp. Net | $0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$1 | -$2 | -$1 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | $5 | -$2 | -$9 |
| % Margin | – | – | – | -1,278.4% |
| EPS | -0.022 | -1.29 | -9.37 | -0.13 |
| % Growth | 98.3% | 86.2% | -7,107.7% | – |
| EPS Diluted | -0.022 | -1.29 | -9.37 | -0.13 |
| Weighted Avg Shares Out | 42 | 26 | 1 | 80 |
| Weighted Avg Shares Out Dil | 42 | 26 | 1 | 80 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $1 |
| EBITDA | -$0 | -$2 | -$1 | -$8 |
| % Margin | – | – | – | -1,163.3% |